Navigation Links
Novel toxin receptor discovered for ulcer-causing stomach pathogen
Date:5/23/2008

Helicobacter pylori is one tough bug. It can survive in the human stomach, a zone with a pH somewhere between that of lemon juice and battery acid. Now researchers have discovered how an H. pylori toxin gets into cells, a feat that helps the bacterium live in one of the most inhospitable environments in the body.

Their findings appear this week in PLoS Pathogens, a journal of the Public Library of Science.

About half of the worlds population is infected with H. pylori, although most of them dont know it (most infected people have no obvious symptoms). For a percentage of the infected, however, the bacterium packs a nasty punch. H. pylori is responsible for most human cases of gastric and duodenal ulcers, and long-term infection is a significant risk factor for stomach cancer, the second leading cause of cancer death worldwide.

Researchers have tried for years to understand how the bacterium survives in the human stomach, said Steven Blanke, a University of Illinois professor in the department of microbiology and Institute for Genomic Biology and principal investigator on the study.

Paradoxically, although H. pylori is a common resident of the human stomach, the bug is not well adapted by itself to acid, he said. But this pathogen has several clever mechanisms for carving out a niche for itself in the stomach lining.

A protein produced by H. pylori, called vacuolating toxin A (VacA), is an important weapon in its arsenal.

This toxin gets into stomach epithelial cells and immune cells and changes their properties in such a way as to allow H. pylori to first gain a foothold in the stomach, and then survive over the long-term, which may be the entire lifetime of an individual, Blanke said.

H. pylori releases the VacA toxin in order to modify its environment, he said.

How the toxin crossed the membrane to get into these cells was a mystery, however.

Cell membranes are composed prima
'/>"/>

Contact: Diana Yates
diya@illinois.edu
217-333-5802
University of Illinois at Urbana-Champaign
Source:Eurekalert  

Page: 1 2 3

Related medicine news :

1. Novel enzyme inhibitor paves way for new cancer drug
2. Abbott to Present Data on Novel Cancer Treatments at American Society of Clinical Oncology Annual Meeting
3. Novel mechanisms controlling insulin release and fat deposition discovered
4. Preliminary Results from Phase 2 Genzyme Study Highlight Potential of Novel Oral Compound for Gaucher Disease
5. Discovery of a novel mechanism for the development of colon cancer
6. TorreyPines Therapeutics Licenses Intellectual Property from Johns Hopkins Related to Novel Uses of Glutamate Receptor Antagonists for Prevention, Treatment of Stroke, Heart Attack
7. Latona Announces the Acquistion of Patent Rights and Orphan Drug Status to Novel Late Stage Drug Compound for Juvenile and Adult Rheumatoid Arthritis
8. Scientists identify novel way to prevent cardiac fibrosis
9. Registry unveils real-world data on novel excel stent
10. Researchers sharpen search for new marine medicines with novel techniques
11. Increased hepcidin expression: A novel oncogenic signalling mechanism
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
Novel toxin receptor discovered for ulcer-causing stomach pathogen
(Date:5/4/2015)... TROY Healthcare Solutions is proud to be a ... (RUG) Conference in Baltimore, MD from May 11 – ... provides an opportunity for clients to gather to network, ... In addition to sponsoring the event, TROY Healthcare Solutions ... Conference. Attendees can stop by the TROY booth and ...
(Date:5/4/2015)... In May of 2010, after two years of constant ... wake of this tragedy, Ty’s parents Kirk and Laura Smalley ... grim reality of bullying and its devastating consequences. Stand for ... to share their story and offer education and tools that ... — a mission that took the Smalley family all the ...
(Date:5/4/2015)... DC (PRWEB) May 04, 2015 EY ... Kit Check as a finalist for the EY Entrepreneur ... Region. The awards program recognizes entrepreneurs who demonstrate ... financial performance and personal commitment to their businesses and ... by a panel of independent judges. Award winners ...
(Date:5/4/2015)... Ill., (PRWEB) May 04, 2015 New ... American Brain Tumor Association (ABTA) show that people diagnosed ... diagnosis and treatment options, including clinical trials, at the ... days to make difficult decisions about their course of ... launch of the first nationwide brain tumor volunteer network, ...
(Date:5/4/2015)... 2015 Dr. Benjamin Stong of Kalos ... the latest non-surgical double-chin eliminator. Dr. Stong is ... in Atlanta to offer Kybella treatments . The ... specifically under the chin, promising to safely dissolve fat ... patients who sought immediate solutions for their double chin ...
Breaking Medicine News(10 mins):Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 2Health News:TROY Healthcare to Exhibit at the Cerner North Atlantic Regional User Group Conference 3Health News:WWE Legend "Rowdy" Roddy Piper Teams Up with Stand for the Silent for Timely Anti-Bullying Campaign 2Health News:WWE Legend "Rowdy" Roddy Piper Teams Up with Stand for the Silent for Timely Anti-Bullying Campaign 3Health News:EY announces Kit Check CEO and Co-founder Kevin MacDonald as an EY Entrepreneur Of The Year® 2015 Award finalist in the Greater Washington Region 2Health News:American Brain Tumor Association Poll Underscores Need for Greater Awareness and Education at Time of Diagnosis 2Health News:American Brain Tumor Association Poll Underscores Need for Greater Awareness and Education at Time of Diagnosis 3Health News:Facial Plastic Surgeon First in Atlanta To Offer Kybella Treatments To Reduce Chin Fat 2
... LAKEWOOD, Colo., Nov. 7 Mesa Laboratories,Inc. (Nasdaq: MLAB ... fiscal second quarter and six months ended September 30, 2007. ... 16% * Second quarter net income increases ... 39% For the second quarter of fiscal 2008, net ...
... cut their risk for neurodevelopmental trouble, researchers say, , , ... they couldn,t live without their morning coffee, but caffeine ... tiny premature infants. , New research finds that high ... early -- an average of 27 weeks gestation -- ...
... is ,Biomedical and Health Informatics, From,Foundations to ... 7 The American Medical,Informatics Association (AMIA) ... research and development in biomedical and health,informatics ... of hot topics,including privacy and security of ...
... Nov. 7 Isolagen(TM), Inc. (Amex:,ILE) announces the initiation ... for the treatment of moderate to severe,acne scars. Isolagen ... evaluate the Isolagen Therapy in treating nasolabial folds, or ... from acne which often scars, a,condition that can be ...
... drug program the largest of its kind, CLEVELAND, ... improving the health and wellness of its customers,supermarket retailer ... 8, 2007, the company will expand its popular $4 ... than 400. The program makes commonly prescribed dosages, ...
... But Zocor, a statin, still offers significant heart benefits, ... Lowering your cholesterol could interrupt your slumber. , A ... patterns in some users. , "The study suggests that ... said Dr. Sidney Smith, past president of the American ...
Cached Medicine News:Health News:Mesa Labs Reports Higher Quarterly Sales and Earnings 2Health News:Mesa Labs Reports Higher Quarterly Sales and Earnings 3Health News:Mesa Labs Reports Higher Quarterly Sales and Earnings 4Health News:Mesa Labs Reports Higher Quarterly Sales and Earnings 5Health News:Caffeine Therapy Boosts Preemies' Outcomes 2Health News:Caffeine Therapy Boosts Preemies' Outcomes 3Health News:AMIA's 31st Annual Symposium Opens in Chicago, IL 2Health News:AMIA's 31st Annual Symposium Opens in Chicago, IL 3Health News:Isolagen Initiates Phase III Clinical Program to Investigate Isolagen Therapy(TM) for the Treatment of Acne Scars 2Health News:Isolagen Initiates Phase III Clinical Program to Investigate Isolagen Therapy(TM) for the Treatment of Acne Scars 3Health News:Giant Eagle Expands Popular Generic Prescription Program and Now Offers '400 for $4' 2Health News:Cholesterol Drug Tied to Sleep Disturbances 2
(Date:5/4/2015)... SOMERSET, N.J. , May 4, 2015 ... 20 percent seek help. During May – National Hearing ... hearing loss could be missing out on the sounds ... through the trees. To ensure that you ... sounds that color our world, Oticon, Inc. offers practical ...
(Date:5/4/2015)... -- Impax Laboratories, Inc. (NASDAQ: IPXL ) announced that ...  Donna M. Hughes, as Senior Vice President, Human Resources ... President, Chief Compliance Officer. Both Ms. Hughes and Ms. ... Officer, Fred Wilkinson . "We are ... team," said Fred Wilkinson , President and Chief ...
(Date:5/4/2015)... Bayer HealthCare (Bayer) has entered into an ... ISIS ) on ISIS-FXI Rx, an antisense investigational ... Under the agreement Bayer will further develop and commercialize ... need. As part of the clinical development program, Bayer ... in an appropriate patient community. "Bayer ...
Breaking Medicine Technology:It's Better Hearing Month 2Impax Strengthens Leadership Team by Adding New Senior Vice Presidents for Human Resources and Compliance 2Impax Strengthens Leadership Team by Adding New Senior Vice Presidents for Human Resources and Compliance 3Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 2Bayer Licenses Investigational ISIS FXI(Rx) from Isis Pharmaceuticals to Develop and Commercialize for the Prevention of Thrombosis 3
... ... at ADA 2008, ... today announced data showing that the use of mealtime,SYMLIN(R) (pramlintide acetate) ... achieving diabetes treatment goals of,improved glucose control without weight gain or ...
... Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced today ... with AZ-002 (Staccato(R),alprazolam) in patients with panic disorder. ... which were the effect of AZ-002 on the ... of AZ-002 on the duration of a,doxapram-induced panic ...
Cached Medicine Technology:Use of Mealtime SYMLIN(R) Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes Using Basal Insulin 2Use of Mealtime SYMLIN(R) Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes Using Basal Insulin 3Use of Mealtime SYMLIN(R) Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes Using Basal Insulin 4Use of Mealtime SYMLIN(R) Compared to Rapid-Acting Insulin for Diabetes Therapy Intensification in Patients With Type 2 Diabetes Using Basal Insulin 5Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder 2Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder 3Alexza Announces Preliminary Results From its AZ-002 (Staccato(R) Alprazolam) Phase 2a Proof-of-Concept Trial in Patients With Panic Disorder 4
Sonogage introduces a new generation of A-Scan biometers for visual axis measurements and IOL calculations. The Eye-Scan™ employs the latest electronic and transducer technologies for unsurpass...
Improve your refractive outcome, with AXIS II precision biometry A-scan. Biometry clinically proven as accurate as partial coherence interferometry while not limited by dense media....
... measurement modes (Phakic, Aphakic, and IOL mode), ... length measuring mode. Normal phakic mode measures ... conversion at 1550m/s. The new Phakic 2 ... sonic velocity for conversion: anterior chamber and ...
... Combination A-Scan/Pachymeter with graphic display ... A-scans and A-Scan/Pachymeter combination units include ... Dioptimum and Binkhorst II formulas. Audible ... you get to visual axis. Constant ...
Medicine Products: